Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 11/20 | 0.63 |
| ▸ | LDHB | P07195 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 5/20 | 0.49 |
| ▸ | NEK2 | P51955 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CCNH | P51946 | 1/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15201610 | 0.81 | ATR (0.64) | ATRFYNNEK2PRKDCATM | |
| SCHEMBL6701889 | 0.81 | ADORA1 (0.56) | ATRPRKDCATM | |
| SCHEMBL934795 | 0.81 | ADORA1 (0.56) | ATRPRKDCATM | |
| SCHEMBL6696482 | 0.80 | PIK3CG (0.55) | ATRNEK2PRKDCATM | |
| SCHEMBL2934913 | 0.80 | ATR (0.67) | ATR | |
| SCHEMBL11909553 | 0.80 | ATR (0.72) | ATRLDHBPRKDCATM | |
| SCHEMBL3460497 | 0.80 | ATR (0.71) | ATRLDHBFYNPRKDCATM | |
| SCHEMBL10309257 | 0.79 | ATR (0.60) | ATRLDHBPRKDCATM | |
| SCHEMBL2931488 | 0.79 | NEK2 (0.64) | ATRLDHBNEK2PRKDCATM | |
| SCHEMBL4620367 | 0.78 | FYN (0.76) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| CN-101472912-A | Pyridine and pyrazine derivatives as MNK kinase inhibitors | BIOVITRUM AB PUBL (SE) | 2009-07-01 | — | — | CN | disclosed |
| EP-2044051-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (publ) (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | ATR 556/4885LDHB 3704/4885FYN 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.